<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN" "JATS-journalpublishing1-4.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.4" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">ojemd</journal-id>
      <journal-title-group>
        <journal-title>Open Journal of Endocrine and Metabolic Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2165-7432</issn>
      <issn pub-type="ppub">2165-7424</issn>
      <publisher>
        <publisher-name>Scientific Research Publishing</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.4236/ojemd.2026.163009</article-id>
      <article-id pub-id-type="publisher-id">ojemd-150179</article-id>
      <article-categories>
        <subj-group>
          <subject>Article</subject>
        </subj-group>
        <subj-group>
          <subject>Medicine</subject>
          <subject>Healthcare</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Hyperthyroidism during Pregnancy: Clinical and Paraclinical Features and Maternal-Fetal Outcomes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sall</surname>
            <given-names>Sokhna Awa Balla</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Diack</surname>
            <given-names>Ngoné Diaba</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mbaye</surname>
            <given-names>Khadim</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ndour</surname>
            <given-names>Simon Birame</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ouazzani</surname>
            <given-names>Zineb</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ba</surname>
            <given-names>Mamadou</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Diallo</surname>
            <given-names>Abdou Karim</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ndiaye</surname>
            <given-names>Nafy</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leye</surname>
            <given-names>Mohamed Yakham</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mbaye</surname>
            <given-names>Alassane</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Diouf</surname>
            <given-names>Abdoul Aziz</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leye</surname>
            <given-names>Abdoulaye</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label> Endocrinology-Metabolism-Nutrition Department, Pikine National Hospital, Dakar, Senegal </aff>
      <aff id="aff2"><label>2</label> Gynecology and Obstetrics Department, Pikine National Hospital, Dakar, Senegal </aff>
      <aff id="aff3"><label>3</label> Cardiology Department, Idrissa Pouye General Hospital, Dakar, Senegal </aff>
      <author-notes>
        <fn fn-type="conflict" id="fn-conflict">
          <p>The authors declare no conflicts of interest regarding the publication of this paper.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>03</month>
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>03</month>
        <year>2026</year>
      </pub-date>
      <volume>16</volume>
      <issue>03</issue>
      <fpage>73</fpage>
      <lpage>88</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>12</month>
          <year>2025</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>03</month>
          <year>2026</year>
        </date>
        <date date-type="published">
          <day>17</day>
          <month>03</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2026 by the authors and Scientific Research Publishing Inc.</copyright-statement>
        <copyright-year>2026</copyright-year>
        <license license-type="open-access">
          <license-p> This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link> ). </license-p>
        </license>
      </permissions>
      <self-uri content-type="doi" xlink:href="https://doi.org/10.4236/ojemd.2026.163009">https://doi.org/10.4236/ojemd.2026.163009</self-uri>
      <abstract>
        <p><bold>Introduction:</bold> During pregnancy, changes cause physiological hyperfunction of the thyroid gland. In some cases, this thyroid hyperfunction can be pathological. Therefore, we aimed to determine the clinical and biological aspects, and maternal-fetal complications of this condition in a Dakar hospital setting. <bold>Meth</bold><bold>odology:</bold> We conducted a prospective and retrospective descriptive study for analytical purposes covering the period from January 1, 2018, to June 30, 2023, in the Endocrinology-Diabetology-Nutrition Department of the Pikine National Hospital Center. All patients monitored for hyperthyroidism during pregnancy during this period were included. <bold>Results:</bold> Forty patients were included. The prevalence of pregnancy among women followed for hyperthyroidism was 2%. The average age was 29.63 years. Most patients had thyrotoxicosis syndrome and goiter. Acquired exophthalmos was present in 45% of patients. The mean T4L was 39.19 pmol/L. The most common etiology was Graves’ disease. Benzylthiouracil was the most commonly prescribed ATS. The mean gestational age at the first endocrinology consultation was 14 weeks. Obstetric pathologies were found in 52.5% of patients. The most common route of delivery was vaginal. Subsequently, three patients underwent total thyroidectomy. <bold>Conclusion:</bold> Severity is associated with a higher risk of complications. Multidisciplinary collaboration and appropriate follow-up are essential as they determine the prognosis.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated" xml:lang="en">
        <kwd>Hyperthyroidism</kwd>
        <kwd>Pregnancy</kwd>
        <kwd>Fetal</kwd>
        <kwd>Etiology</kwd>
        <kwd>Complications</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>1. Introduction</title>
      <p>During pregnancy, dynamic changes in thyroid homeostasis are observed, leading to a 50% increase in thyroid hormone synthesis [<xref ref-type="bibr" rid="B1">1</xref>]. These physiological changes specific to pregnancy are necessary to meet increased hormonal needs, especially during the first half of gestation [<xref ref-type="bibr" rid="B1">1</xref>][<xref ref-type="bibr" rid="B2">2</xref>]. In some cases, this physiological hyperfunction of the thyroid during pregnancy can be pathological. Persistent, uncontrolled hyperthyroidism can lead to obstetric and/or neonatal complications [<xref ref-type="bibr" rid="B3">3</xref>]. The risk of complications correlates with the degree of hyperthyroidism [<xref ref-type="bibr" rid="B2">2</xref>]. Hyperthyroidism occurs in approximately 2% - 3% of pregnancies [<xref ref-type="bibr" rid="B3">3</xref>]. It is linked to Graves’ disease in 90% - 95% of cases [<xref ref-type="bibr" rid="B2">2</xref>]. The difficulty in managing hyperthyroidism during pregnancy is related to the teratogenic effect of synthetic antithyroid drugs (SATs) and the frequency of monitoring [<xref ref-type="bibr" rid="B4">4</xref>]. In Senegal, the latest data on the prevalence of hyperthyroidism during pregnancy date back to 2003 and was 0.1% [<xref ref-type="bibr" rid="B5">5</xref>]. Thus, we conducted this study in one of the main Endocrinology-Diabetology-Nutrition departments in Dakar (National Hospital Center of Pikine). The objectives of this study were to determine:</p>
      <p>The clinical and biological aspects,The maternal and fetal complications resulting from this combination in our patients.</p>
    </sec>
    <sec id="sec2">
      <title>2. Methodology</title>
      <p>Our study was conducted in the Endocrinology–Diabetology–Nutrition, Gynecology, and Otolaryngology departments of the National Hospital Center of Pikine (CHNP) in Dakar, Senegal.</p>
      <p>This was a retrospective and prospective, descriptive study with analytical purposes, monocentric, over a 66-month period from January 2018 to June 2023.</p>
      <p>All patients followed in the aforementioned departments of the CHN of Pikine presenting one of the following situations were included:</p>
      <p>Occurrence of pregnancy in a patient followed for hyperthyroidism, confirmed by a positive urinary pregnancy test and/or ultrasound evidence of pregnancy, or serum <italic>β</italic>-hCG levels greater than 5 IU/L.Identification of clinico-biological thyrotoxicosis in a pregnant woman:With suppressed TSH:Less than 0.1 mIU/L in the first trimester,Less than 0.2 mIU/L in the second trimester,Less than 0.3 mIU/L in the third trimester,And elevated free T4 greater than 22 pmol/L.</p>
      <p>Hyperemesis gravidarum–related gestational transient thyrotoxicosis was differentiated from pathological hyperthyroidism based on clinical, biological, and evolutionary criteria. Transient hCG-mediated thyrotoxicosis was suspected in the presence of severe vomiting without prior history of thyroid disease, absence of goiter and extrathyroidal signs (particularly exophthalmos), mildly elevated free T4 levels, and spontaneous clinical and biochemical improvement with supportive treatment alone.</p>
      <p>The following parameters were studied:</p>
      <p>Data on hyperthyroidism: duration, regularity of follow-up, severity of hyperthyroidism, etiology, treatment, and follow-up of hyperthyroidism.</p>
      <p>Hyperthyroidism was considered severe if any of the following criteria were met: </p>
      <p>Need for hospitalization, Presence of a complication such as cardiothyreosis or acute thyrotoxic crisis; T4L greater than 40 pmol/L.Pregnancy data: Gestational age at the first consultation, pregnancy monitoring, obstetric pathologies, delivery data, neonatal data, pregnancy progression. </p>
      <p>Neonatal hypotrophy is defined as a birth weight of less than 2500 grams during a full-term pregnancy.</p>
      <p>Evolutionary Data: time between delivery and consultation, postpartum contraception, subsequent care.</p>
      <p>Data were collected using a pre-established form and entered using SPSS software (Statistical Package for the Social Sciences), version 2.</p>
      <p>Descriptive analysis was performed by calculating frequencies and proportions for qualitative variables and means for quantitative variables, with standard deviation.</p>
      <p>The analytical study was conducted using cross-tabulation tables. To compare frequencies, we used Pearson's chi-square test or Fisher's exact two-tailed test, depending on their applicability. Means were compared using analysis of variance with a significance threshold of p &lt; 0.05. Text processing was performed using Word XP Professional software.</p>
      <p>In the discussion, the studied parameters were compared with data from the literature, and hypotheses were formulated.</p>
    </sec>
    <sec id="sec3">
      <title>3. Results</title>
      <p><bold>Descriptive Study</bold></p>
      <p>During the study period, 40 patients had the study criteria.</p>
      <p>A total of 1946 patients consulted for hyperthyroidism during this period.Among them, 40 patients were pregnant, corresponding to a hospital prevalence of 2%.</p>
      <p>The mean age of patients in our study was 29.63 years, with extremes of 18 and 39 years and a standard deviation of 6.44.</p>
      <p><bold>Hyperthyroidism Data</bold><bold>Duration</bold></p>
      <p>Hyperthyroidism was diagnosed before pregnancy in 72.5% of patients.The mean duration of hyperthyroidism was 28 months, with extremes of 5 months and 120 months (10 years) and a standard deviation of 31.01. The duration of hyperthyroidism exceeded 5 years in 21% of patients, was between 1 and 4 years in 55%, and less than 1 year in 24% of patients.</p>
      <p><bold>Follow-up Regularity</bold></p>
      <p>Among the 29 patients previously followed for hyperthyroidism, 13 had irregular follow-up with voluntary treatment interruptions ranging from 1 month to 3 years.</p>
      <p>All patients with regular follow-up were on antithyroid drugs (ATDs) at the time of pregnancy diagnosis, and two of them were on propranolol. Previous treatments of patients are presented in <bold>Table 1</bold>.</p>
      <p><bold>Table 1.</bold>Distribution of patients according to treatment among regularly followed hyperthyroid patients.</p>
      <table-wrap id="tbl1">
        <label>Table 1</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>Antithyroid Drugs (ATD)</bold>
              </td>
              <td>
                <bold>Number (N</bold>
                <bold>=</bold>
                <bold>16)</bold>
              </td>
              <td>
                <bold>Percentage (%)</bold>
              </td>
            </tr>
            <tr>
              <td>Carbimazole</td>
              <td>11</td>
              <td>69</td>
            </tr>
            <tr>
              <td>Thiamazole</td>
              <td>4</td>
              <td>25</td>
            </tr>
            <tr>
              <td>Benzylthiouracil</td>
              <td>1</td>
              <td>6</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p><bold>Clinical Data at First Consultation</bold></p>
      <p><bold>Clinical Signs of Hyperthyroidism at First Consultation</bold></p>
      <p>A thyrotoxic syndrome was observed in 82.5% of patients at the first consultation (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p>
      <fig id="fig1">
        <label>Figure 1</label>
        <graphic xlink:href="https://html.scirp.org/file/1980557-rId13.jpeg?20260317104732" />
      </fig>
      <p><bold>Figure 1.</bold>Distribution of patients according to the presence of thyrotoxic syndrome at the first consultation.</p>
      <p>Vital signs are summarized in <bold>Table 2</bold>.</p>
      <p><bold>Table 2.</bold>Distribution of patients according to vital signs and measurements at first consultation.</p>
      <table-wrap id="tbl2">
        <label>Table 2</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>Vital Signs at First Consultation</bold>
              </td>
              <td>
                <bold>Mean</bold>
              </td>
              <td>
                <bold>Range</bold>
              </td>
            </tr>
            <tr>
              <td>Heart rate (beats per minute)</td>
              <td>98.12</td>
              <td>51 - 150</td>
            </tr>
            <tr>
              <td>Systolic blood pressure (mmHg)</td>
              <td>126</td>
              <td>100 - 160</td>
            </tr>
            <tr>
              <td>Diastolic blood pressure (mmHg)</td>
              <td>77.5</td>
              <td>60 - 102</td>
            </tr>
            <tr>
              <td>Mean gestational weight (kgs)</td>
              <td>62.92</td>
              <td>43 - 80</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Weight loss was reported in 57.5% of patients.</p>
      <p><bold>Goiter at First Consultation</bold></p>
      <p>Goiter was observed in 37 patients (92.5%). It was nodular on palpation in five patients. Goiter stage is summarized in <bold>Table 3</bold>.</p>
      <p><bold>Table 3.</bold>Distribution of patients according to goiter stage.</p>
      <table-wrap id="tbl3">
        <label>Table 3</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>WHO Goiter Stage</bold>
              </td>
              <td>
                <bold>Number (N</bold>
                <bold>=</bold>
                <bold>40)</bold>
              </td>
              <td>
                <bold>Percentage (%)</bold>
              </td>
            </tr>
            <tr>
              <td>Stage I</td>
              <td>20</td>
              <td>50</td>
            </tr>
            <tr>
              <td>Stage II</td>
              <td>11</td>
              <td>26</td>
            </tr>
            <tr>
              <td>Stage III</td>
              <td>9</td>
              <td>24</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>It was vascularized in 50% of cases.</p>
      <p><bold>Exophthalmos at First Consultation</bold></p>
      <p>Acquired exophthalmos was present in 18 patients (45%), and unilateral in one patient (2.5%). None of the patients showed signs of malignancy.</p>
      <p><bold>Paraclinical Data</bold></p>
      <p><bold>Thyroid Hormones</bold></p>
      <p>Initial thyroid function tests were performed at the beginning of pregnancy in 28 patients (<bold>Table 4</bold>).</p>
      <p><bold>Table 4.</bold>Distribution of patients according to thyroid function at early pregnancy.</p>
      <table-wrap id="tbl4">
        <label>Table 4</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>Thyroid Function</bold>
              </td>
              <td>
                <bold>Number (N</bold>
                <bold>=</bold>
                <bold>40)</bold>
              </td>
              <td>
                <bold>Percentage (%)</bold>
              </td>
            </tr>
            <tr>
              <td>Hyperthyroidism</td>
              <td>21</td>
              <td>52.5</td>
            </tr>
            <tr>
              <td>Euthyroidism</td>
              <td>6</td>
              <td>15</td>
            </tr>
            <tr>
              <td>Hypothyroidism</td>
              <td>1</td>
              <td>2.5</td>
            </tr>
            <tr>
              <td>Not done</td>
              <td>12</td>
              <td>30</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Hyperthyroidism was found in 52.5% of patients.</p>
      <p>Mean free T4 was 39.19 pmol/L (range: 7 - 68 pmol/L; SD: 18.15 pmol/L). Mean TSH was 0.64 IU/L (range: 0.0001 - 5 IU/L). TRAb was measured in early pregnancy in 3 patients (one negative, two positive with values 1.5 N and 6 N, respectively).</p>
      <fig id="fig2">
        <label>Figure 2</label>
        <graphic xlink:href="https://html.scirp.org/file/1980557-rId14.jpeg?20260317104732" />
      </fig>
      <p><bold>Figure 2.</bold>Distribution of patients according to thyroid ultrasound findings.</p>
      <p><bold>Thyroid Ultrasound</bold></p>
      <p>Thyroid ultrasound was performed in 21 patients. Findings are presented in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p>
      <p><bold>Hyperthyroidism Severity</bold></p>
      <p>Hyperthyroidism was considered severe in 16 patients.</p>
      <p>Hospitalization following the first consultation occurred in 3 patients, with a mean hospital stay of 4.6 days (range: 4 - 6 days).</p>
      <p>Free T4 &gt; 40 pmol/L was observed in 14 patients. Cardiothyreosis was found in 2 patients.</p>
      <p><bold>Etiology of Hyperthyroidism</bold></p>
      <p>Graves’ disease was observed in 80% of patients (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p>
      <fig id="fig3">
        <label>Figure 3</label>
        <graphic xlink:href="https://html.scirp.org/file/1980557-rId15.jpeg?20260317104732" />
      </fig>
      <p><bold>Figure 3.</bold>Distribution of patients according to hyperthyroidism etiology.</p>
      <p><bold>Therapeutic Data</bold></p>
      <p>Antithyroid Drugs (ATD) were prescribed in 87.5% of patients.</p>
      <p>Propranolol was prescribed in 40% of patients. Treatment is summarized in <bold>Table 5</bold>.</p>
      <p><bold>Table 5.</bold>Distribution of patients according to hyperthyroidism treatment.</p>
      <table-wrap id="tbl5">
        <label>Table 5</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>Treatment</bold>
              </td>
              <td>
                <bold>Number (N</bold>
                <bold>=</bold>
                <bold>40)</bold>
              </td>
              <td>
                <bold>Percentage (%)</bold>
              </td>
            </tr>
            <tr>
              <td colspan="3">
                <bold>Specific hyperthyroidism treatment</bold>
              </td>
            </tr>
            <tr>
              <td>Benzylthiouracil</td>
              <td>16</td>
              <td>40</td>
            </tr>
            <tr>
              <td>Carbimazole</td>
              <td>12</td>
              <td>30</td>
            </tr>
            <tr>
              <td>Propylthiouracil</td>
              <td>4</td>
              <td>10</td>
            </tr>
            <tr>
              <td>Thiamazole</td>
              <td>3</td>
              <td>7.5</td>
            </tr>
            <tr>
              <td>No ATD</td>
              <td>5</td>
              <td>12.5</td>
            </tr>
            <tr>
              <td colspan="3">
                <bold>Symptomatic treatment</bold>
              </td>
            </tr>
            <tr>
              <td>Propranolol</td>
              <td>16</td>
              <td>40</td>
            </tr>
            <tr>
              <td>Corticosteroids</td>
              <td>2</td>
              <td>5</td>
            </tr>
            <tr>
              <td>Anxiolytics</td>
              <td>1</td>
              <td>2.5</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p><bold>Hyperthyroidism Evolution</bold><bold>(</bold><xref ref-type="fig" rid="fig4">Figure 4</xref><bold>)</bold>Endocrinology follow-up was discontinued during pregnancy in 11 patients.Treatment interruption was reported in 5 patients.The mean number of free T4 measurements during pregnancy was 1 (range 1 - 3).Regarding hyperthyroidism complications, 5% had cardiothyreosis and 50% had persistent hyperthyroidism throughout pregnancy.</p>
      <fig id="fig4">
        <label>Figure 4</label>
        <graphic xlink:href="https://html.scirp.org/file/1980557-rId16.jpeg?20260317104732" />
      </fig>
      <p><bold>Figure 4.</bold>Distribution of patients according to clinico-biological evolution of hyperthyroidism during pregnancy.</p>
      <p>One patient transitioned from Graves’ disease to Hashimoto’s thyroiditis during pregnancy.</p>
      <p><bold>Pregnancy Data</bold></p>
      <p>Among included patients, 52% reported not being informed about the need for contraception.</p>
      <p><bold>Gestational Age at First Endocrinology Consultation</bold></p>
      <p>Mean gestational age was 14 weeks of amenorrhea (range 6 - 34 weeks) (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p>
      <fig id="fig5">
        <label>Figure 5</label>
        <graphic xlink:href="https://html.scirp.org/file/1980557-rId17.jpeg?20260317104732" />
      </fig>
      <p><bold>Figure 5.</bold>Distribution of patients according to gestational age at first endocrinology consultation.</p>
      <p><bold>Pregnancy Follow-up</bold></p>
      <p>The mean number of prenatal consultations was 3.18 (range 1 - 6). One patient did not complete prenatal work-up.</p>
      <p>During pregnancy, five patients developed anemia, and one had SARS-CoV-2 pneumonia.</p>
      <p>Obstetric ultrasound was performed in all patients (range: 1 - 5), with a mean of 2.5 scans.</p>
      <p>Two patients discontinued obstetric follow-up during pregnancy.</p>
      <p><bold>Obstetric and Fetal Complications</bold></p>
      <p>Obstetric and/or fetal pathologies were observed in 21 patients (<bold>Table 6</bold>).</p>
      <p><bold>Table 6.</bold>Distribution of patients according to obstetric and fetal complications.</p>
      <table-wrap id="tbl6">
        <label>Table 6</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>Obstetric/Fetal Complication</bold>
              </td>
              <td>
                <bold>Number (N</bold>
                <bold>=</bold>
                <bold>40)</bold>
              </td>
              <td>
                <bold>Percentage (%)</bold>
              </td>
            </tr>
            <tr>
              <td>Miscarriage</td>
              <td>6</td>
              <td>15</td>
            </tr>
            <tr>
              <td>Intrauterine fetal death (IUFD)</td>
              <td>4</td>
              <td>10</td>
            </tr>
            <tr>
              <td>Retroplacental hematoma</td>
              <td>3</td>
              <td>7.5</td>
            </tr>
            <tr>
              <td>Hypertensive disorders of pregnancy</td>
              <td>3</td>
              <td>7.5</td>
            </tr>
            <tr>
              <td>Post-term pregnancy</td>
              <td>2</td>
              <td>5</td>
            </tr>
            <tr>
              <td>Prolonged pregnancy</td>
              <td>2</td>
              <td>5</td>
            </tr>
            <tr>
              <td>Threatened preterm labor</td>
              <td>2</td>
              <td>5</td>
            </tr>
            <tr>
              <td>Premature rupture of membranes</td>
              <td>1</td>
              <td>2.5</td>
            </tr>
            <tr>
              <td>Intrauterine growth restriction</td>
              <td>1</td>
              <td>2.5</td>
            </tr>
            <tr>
              <td>Oligohydramnios</td>
              <td>1</td>
              <td>2.5</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>One patient was treated with Nifedipine, one with Loxen, one with Aldomet, and one with Utrogestan.</p>
      <p><bold>Delivery Data</bold></p>
      <p>Three pregnancies were ongoing at the time of the study. Miscarriage occurred </p>
      <fig id="fig6">
        <label>Figure 6</label>
        <graphic xlink:href="https://html.scirp.org/file/1980557-rId18.jpeg?20260317104732" />
      </fig>
      <p><bold>Figure 6.</bold> Distribution of neonates according to complications.</p>
      <p>in 6 patients. Delivery occurred in 31 patients, with a mean gestational age of 37.7 weeks (range 24 - 42 weeks).</p>
      <p>Vaginal delivery occurred in 68% of patients; low transverse cesarean section in 32%. One patient delivered prematurely at 33 weeks.</p>
      <p><bold>Neonatal Data</bold></p>
      <p>The perinatal period was defined between 22 weeks of gestation and day 6. Among 31 live births, 7 neonates had complications (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p>
      <p>TSH measurement was performed in two neonates: one had hypothyroidism, and one was normal.</p>
      <p><bold>Evolutionary Data</bold><bold>Postpartum Hyperthyroidism Follow-up</bold></p>
      <p>Mean duration from first endocrinology consultation postpartum was 3.6 months (range 10 days - 6 years).</p>
      <p>Among postpartum patients, 60% continued regular follow-up, 16% irregular, and 24% discontinued.</p>
      <p>Among the 22 regularly followed patients, 18 were euthyroid and 4 hyperthyroid.</p>
      <p>TRAb was measured in 4 patients, mean 4.23, with 3 positive (range 0.34 - 6.94).</p>
      <p>All 22 regularly followed patients continued ATD therapy: 12 on carbimazole, 8 on thyrozole, 3 on benzylthiouracil. Nine received beta-blockers, one anxiolytics.</p>
      <p><bold>Gynecological and Obstetric Follow-up</bold></p>
      <p>Two patients became pregnant before completing hyperthyroidism management.</p>
      <p>After delivery, only one patient reported not being informed of contraception until euthyroid status was achieved. Among 22 regularly followed patients, 5 accepted contraception (intrauterine device). The remaining 17 refused, mainly due to fear of contraception.</p>
      <p>One patient had persistent hypertension postpartum.</p>
      <p><bold>One-Year Follow-up</bold></p>
      <p>Among patients with Graves’ disease, one patient achieved remission with negative TRAb.</p>
      <p><bold>Table 7.</bold>Distribution of patients according to thyroidectomy postpartum.</p>
      <table-wrap id="tbl7">
        <label>Table 7</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>Total Thyroidectomy</bold>
              </td>
              <td>
                <bold>Number (N</bold>
                <bold>=</bold>
                <bold>37)</bold>
              </td>
              <td>
                <bold>Percentage (%)</bold>
              </td>
            </tr>
            <tr>
              <td>Yes</td>
              <td>3</td>
              <td>8</td>
            </tr>
            <tr>
              <td>No</td>
              <td>32</td>
              <td>78</td>
            </tr>
            <tr>
              <td>Pending</td>
              <td>5</td>
              <td>14</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Three patients underwent total thyroidectomy, five were pending. Two available histopathology results confirmed Graves’ disease. No patient received radioactive iodine therapy (<bold>Table 7</bold>).</p>
      <p><bold>Analytical Study</bold><bold>Comparison of Main Etiologies</bold></p>
      <p>Clinical, biological, and evolutionary characteristics according to hyperthyroidism etiology are summarized in <bold>Table 8</bold>.</p>
      <p><bold>Table 8.</bold>Comparison of main etiology characteristics.</p>
      <table-wrap id="tbl8">
        <label>Table 8</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>Etiologies</bold>
                <bold>Characteristics</bold>
              </td>
              <td>
                <bold>Graves’ Disease</bold>
                <bold>(n</bold>
                <bold>=</bold>
                <bold>32)</bold>
              </td>
              <td>
                <bold>Toxic Nodule</bold>
                <bold>(s)</bold>
                <bold>(n</bold>
                <bold>=</bold>
                <bold>3)</bold>
              </td>
              <td>
                <bold>Transient Gestational Hyperthyroidism (n</bold>
                <bold>=</bold>
                <bold>5)</bold>
              </td>
              <td>
                <bold>p-value</bold>
              </td>
            </tr>
            <tr>
              <td>Age</td>
              <td>29.56 ± 6.66</td>
              <td>28.67 ± 6.51</td>
              <td>30.60 ± 6.07</td>
              <td>0.916</td>
            </tr>
            <tr>
              <td>Mean Gravidity</td>
              <td>2.72 ± 1.75</td>
              <td>2.33 ± 2.31</td>
              <td>4.00 ± 3.08</td>
              <td>0.367</td>
            </tr>
            <tr>
              <td>Mean Parity</td>
              <td>1.31 ± 1.42</td>
              <td>1.00 ± 1.73</td>
              <td>2.00 ± 2.12</td>
              <td>0.592</td>
            </tr>
            <tr>
              <td>Mean TSH</td>
              <td>0.77 ± 2.15</td>
              <td>0.001 ± 0.01</td>
              <td>0.04 ± 0.05</td>
              <td>0.759</td>
            </tr>
            <tr>
              <td>Mean free T4</td>
              <td>38.99 ± 18.69</td>
              <td>39.59 ± 9.85</td>
              <td>40.76 ± 32.17</td>
              <td>0.991</td>
            </tr>
            <tr>
              <td>Obstetric Complications</td>
              <td>59.4% (19/32)</td>
              <td>33.3% (1/3)</td>
              <td>20% (1/5)</td>
              <td>0.205</td>
            </tr>
            <tr>
              <td>IUFD</td>
              <td>12.5% (4/32)</td>
              <td>0% (0/3)</td>
              <td>0% (0/5)</td>
              <td>0.839</td>
            </tr>
            <tr>
              <td>Miscarriage</td>
              <td>18.8% (6/32)</td>
              <td>0% (0/3)</td>
              <td>0% (0/5)</td>
              <td>0.414</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The statistical power for these comparisons is low and p-values should be interpreted with caution.</p>
      <p><bold>Correlation Between Hyperthyroidism Severity and Obstetric Complications</bold></p>
      <p>A non-significant positive correlation was observed between hyperthyroidism severity (free T4 at first consultation) and obstetric complications (<bold>Table 9</bold>).</p>
      <p><bold>Table 9.</bold>Correlation between free T4 levels and obstetric complications.</p>
      <table-wrap id="tbl9">
        <label>Table 9</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>Obstetric Complications</bold>
                <bold>T4 (pmol/L)</bold>
              </td>
              <td>
                <bold>Yes</bold>
              </td>
              <td>
                <bold>No</bold>
              </td>
              <td>
                <bold>Total</bold>
              </td>
              <td>
                <bold>p</bold>
              </td>
            </tr>
            <tr>
              <td>&lt;12</td>
              <td>0%</td>
              <td>23.1%</td>
              <td>11.1%</td>
              <td>0.098</td>
            </tr>
            <tr>
              <td>12 - 22</td>
              <td>7.1%</td>
              <td>15.4%</td>
              <td>11.1%</td>
              <td>0.471</td>
            </tr>
            <tr>
              <td>23 - 40</td>
              <td>28.6%</td>
              <td>23.1%</td>
              <td>25.9%</td>
              <td>0.546</td>
            </tr>
            <tr>
              <td>&gt;40</td>
              <td>64.3%</td>
              <td>38.5%</td>
              <td>51.9%</td>
              <td>0.18</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>A positive but non-significant correlation was also observed between hyperthyroidism complications and obstetric pathologies (p = 0.113).</p>
      <p><bold>Relationship Between Extrathyroidal Signs and Obstetric Complications</bold></p>
      <p>The presence of extrathyroidal signs (exophthalmos) was significantly associated with obstetric and fetal complications (p = 0.0024) (<bold>Table 10</bold>).</p>
      <p><bold>Table 10.</bold>Cross-tabulation between extrathyroidal signs and obstetric complications.</p>
      <table-wrap id="tbl10">
        <label>Table 10</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>Obstetric Complications</bold>
                <bold>Exophthalmos</bold>
              </td>
              <td>
                <bold>Yes</bold>
              </td>
              <td>
                <bold>No</bold>
              </td>
              <td>
                <bold>Total</bold>
              </td>
              <td>
                <bold>p</bold>
              </td>
            </tr>
            <tr>
              <td>
                <bold>Yes</bold>
              </td>
              <td>72.2%</td>
              <td>36.4%</td>
              <td>52.5%</td>
              <td>0.028</td>
            </tr>
            <tr>
              <td>
                <bold>No</bold>
              </td>
              <td>27.8%</td>
              <td>63.6%</td>
              <td>47.5%</td>
              <td>0.028</td>
            </tr>
            <tr>
              <td>
                <bold>Total</bold>
              </td>
              <td>100%</td>
              <td>100%</td>
              <td>100%</td>
              <td>0.028</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="sec4">
      <title>4. Discussion</title>
      <p>We conducted a retrospective and prospective descriptive study with an analytical aim over a period of 66 months. This study included 40 patients. A hospital prevalence of pregnancy among women followed for hyperthyroidism of 2% was found. However, this study has several limitations:</p>
      <p>It was a hospital-based study, with a potential overestimation of prevalence.Part of the study was conducted retrospectively, with a possible risk of bias.Difficulties in performing certain biological tests, particularly TSH receptor antibody (TRAb) assays, due to the financial constraints of some patients.</p>
      <p><bold>Data on Hyperthyroidism</bold></p>
      <p>The prevalence reported in our study was 2%, which was higher than that reported in the literature [<xref ref-type="bibr" rid="B6">6</xref>]-[<xref ref-type="bibr" rid="B8">8</xref>] (1.3%). Most patients (72.5%) were already being followed for hyperthyroidism at the beginning of pregnancy.</p>
      <p>Regarding the clinical data at the first consultation, the majority of patients (82.5%) presented with a thyrotoxicosis syndrome. This can be explained by the fact that most patients had been previously diagnosed but were poorly followed. Goiter was found in 92.5% of patients, a rate much higher than that reported in the literature (25% reported by Zakiri <italic>et al.</italic>) [<xref ref-type="bibr" rid="B2">2</xref>]. Acquired exophthalmos was present in 45% of patients, which is also higher than that reported by Zakiri (18.75%) [<xref ref-type="bibr" rid="B2">2</xref>] and Gheorghiu (31.8%) [<xref ref-type="bibr" rid="B4">4</xref>]. This can be explained by the predominance of Graves’ disease in our cohort. The presence of extrathyroidal signs (exophthalmos) was significantly associated with obstetric and fetal pathologies in our study (p = 0.0024). TRAb are present in 100% of patients with dysthyroid orbitopathy [<xref ref-type="bibr" rid="B9">9</xref>], and a strong correlation exists between TRAb levels and the severity of orbitopathy [<xref ref-type="bibr" rid="B9">9</xref>]. Given the lack of TRAb testing in most patients, exophthalmos in our cohort was considered a clinical correlate of TRAb positivity [<xref ref-type="bibr" rid="B9">9</xref>]. Thus, TRAb negativity was associated with a lower risk of obstetric complications. In resource-limited settings, exophthalmos may serve as an orienting clinical marker but doesn’t replace TRAb measurement, which remains the reference standard for immunological assessment. Exophthalmos’absence does not exclude the presence of circulating TRAb. Furthermore, the severity of ocular involvement does not always correlate with antibody titers, particularly during pregnancy, where immunological changes may modify clinical expression.</p>
      <p><bold>Paraclinical Data</bold></p>
      <p>The mean free T4 (FT4) level was 39.19 pmol/L. In our series, hyperthyroidism etiologies were dominated by Graves’ disease (80%), followed by transient gestational thyrotoxicosis, consistent with the series of Livia <italic>et al.</italic> and Abdous <italic>et al.</italic>, where Graves’ disease accounted for 76.6% of cases [<xref ref-type="bibr" rid="B10">10</xref>]. In contrast, the most frequent diagnosis in the series by Zakiri <italic>et al.</italic> was transient gestational thyrotoxicosis (82.5%) [<xref ref-type="bibr" rid="B2">2</xref>]. This difference may be explained by the fact that most of our patients were already diagnosed and followed for Graves’ disease prior to pregnancy.</p>
      <p><bold>Follow-up of Hyperthyroidism</bold></p>
      <p>The recommended frequency of FT4 monitoring described in the literature was not respected in any of our patients. This can be explained, in part, by the lack of financial resources. Monthly hormonal monitoring, as recommended, could not be implemented in our setting due to the high cost of thyroid hormone assays. Several complications are associated with poorly controlled hyperthyroidism during pregnancy [<xref ref-type="bibr" rid="B11">11</xref>]. In our cohort, the two main complications were cardiothyreosis and the absence of remission. The presence of hyperthyroidism-related complications was associated with obstetric pathologies in 65% of cases. All patients who experienced intrauterine fetal death (IUFD) had developed complications related to hyperthyroidism during pregnancy (<xref ref-type="fig" rid="fig7">Figure 7</xref>). In active Graves’ disease, there is an increased risk of heart failure, highlighting the importance of early treatment and follow-up when pregnancy occurs [<xref ref-type="bibr" rid="B12">12</xref>]. Two patients developed cardiothyreosis during pregnancy; both pregnancies were complicated by spontaneous abortion and IUFD. These patients had been diagnosed before pregnancy and had irregular follow-up, with therapeutic discontinuation lasting 4 months and 3 years, respectively.</p>
      <p>Iatrogenic hypothyroidism was reported in 12.5% of patients, which is higher than the rate reported by Chambon (1.9%) [<xref ref-type="bibr" rid="B13">13</xref>]. One patient experienced conversion from Graves’ disease to Hashimoto’s thyroiditis during pregnancy. The literature describes cases of conversion from one autoimmune thyroid disease to another, possibly related to changes in the balance between stimulating and blocking antibodies against the TSH receptor [<xref ref-type="bibr" rid="B14">14</xref>]. Conversion from Graves’ disease to Hashimoto’s thyroiditis appears to be more frequent than the reverse [<xref ref-type="bibr" rid="B14">14</xref>].</p>
      <p><bold>Pregnancy Data</bold></p>
      <p>The mean gestational age at the first endocrinology consultation was 14 weeks of amenorrhea (WA), with extremes ranging from 6 to 34 WA. Compared to the literature, our patients consulted much later, which delayed management.</p>
      <p>Regarding pregnancy follow-up, the mean number of prenatal consultations was 3.18 (range: 1 - 6). For adequate pregnancy follow-up, at least one prenatal consultation per trimester is recommended [<xref ref-type="bibr" rid="B15">15</xref>]. This frequency was not observed in any of our patients.</p>
      <p><bold>Obstetric Complications</bold></p>
      <p>Untreated maternal hyperthyroidism carries significant fetal risks, including growth restriction, threatened preterm labor, and intrauterine fetal death. In our study, we observed six spontaneous abortions, four cases of IUFD, three cases of placental abruption, two cases of gestational hypertension, two cases of threatened preterm labor, and one case of preeclampsia. The number of spontaneous abortions in our study was higher than those reported by Rchachi <italic>et al.</italic>, Zakiri <italic>et al.</italic>, and Abdous <italic>et al.</italic> [<xref ref-type="bibr" rid="B2">2</xref>][<xref ref-type="bibr" rid="B10">10</xref>][<xref ref-type="bibr" rid="B16">16</xref>]. Poorly treated hyperthyroidism in early pregnancy may contribute to spontaneous abortion. All six patients who experienced abortion had severe thyrotoxicosis with a mean FT4 level of 44.74 pmol/L:</p>
      <p>Two were newly diagnosed at the beginning of pregnancy and had never received treatment.Two were previously followed but poorly compliant, with therapeutic discontinuation before pregnancy.Two were regularly followed but had severe clinico-biological hyperthyroidism at pregnancy onset.</p>
      <p>Elevated maternal thyroid hormone levels late in pregnancy may also increase the risk of stillbirth. Our four cases of IUFD exceed those reported by Rchachi <italic>et al.</italic> [<xref ref-type="bibr" rid="B16">16</xref>], who reported none, and Zakiri <italic>et al.</italic> [<xref ref-type="bibr" rid="B2">2</xref>] and Hiéronimus <italic>et al.</italic> [<xref ref-type="bibr" rid="B17">17</xref>], who each reported one case. All four patients were diagnosed before pregnancy and had severe thyrotoxicosis early in pregnancy, with a mean FT4 level of 48.9 pmol/L:</p>
      <p>Three had irregular follow-up with voluntary therapeutic discontinuation before and during pregnancy.One patient was compliant but had persistent hyperthyroidism despite antithyroid drugs and regular follow-up.</p>
      <p>Preeclampsia affects up to 8% of pregnancies worldwide and is a major cause of maternal morbidity and mortality [<xref ref-type="bibr" rid="B18">18</xref>]. Maternal hyperthyroidism has been associated with an increased risk of pregnancy-induced hypertension [<xref ref-type="bibr" rid="B18">18</xref>]. In our study, 5% of patients developed gestational hypertension, 2.5% developed preeclampsia, and three had placental abruption. These rates were lower than those reported by Zakiri and Mannisto (3.1% and 7.9%, respectively) [<xref ref-type="bibr" rid="B2">2</xref>][<xref ref-type="bibr" rid="B19">19</xref>]. All patients with gestational hypertension had severe thyrotoxicosis and irregular follow-up.</p>
      <p>One case of prematurity was reported in our cohort, compared to four cases in Abdous’ series [<xref ref-type="bibr" rid="B10">10</xref>] and six cases in Hiéronimus’ series [<xref ref-type="bibr" rid="B17">17</xref>]. The mean gestational age at delivery was 37 weeks, similar to that reported by Aggarwal and Hiéronimus [<xref ref-type="bibr" rid="B6">6</xref>][<xref ref-type="bibr" rid="B17">17</xref>]. Vaginal delivery was the most frequent mode (68%), consistent with Abdous [<xref ref-type="bibr" rid="B10">10</xref>] and Hiéronimus [<xref ref-type="bibr" rid="B17">17</xref>], but contrasting with Dulek, where cesarean section was more frequent (54%) [<xref ref-type="bibr" rid="B20">20</xref>].</p>
      <p>Only 5% of newborns underwent thyroid hormone testing, as most mothers reported that neonatal screening had not been requested. One case of neonatal hypothyroidism was reported, consistent with Abdous’ findings [<xref ref-type="bibr" rid="B10">10</xref>]. Two cases of fetal growth restriction were observed. In the literature, increased maternal FT4 levels have also been associated with lower birth weight [<xref ref-type="bibr" rid="B21">21</xref>].</p>
      <p><bold>Evolutionary Data</bold></p>
      <p>Postpartum follow-up was discontinued in eight patients and irregular in five patients, mainly due to lack of financial resources. Among regularly followed patients, 22 continued antithyroid drug therapy, with a change in medication for most. Total thyroidectomy was performed after delivery, as no indication for surgery during pregnancy was identified. Two patients became pregnant again before completion of hyperthyroidism management. Most patients refused contraception postpartum, with fear of contraception being the most frequently cited reason.</p>
      <fig id="fig7">
        <label>Figure 7</label>
        <graphic xlink:href="https://html.scirp.org/file/1980557-rId19.jpeg?20260317104732" />
      </fig>
      <p><bold>Figure 7.</bold>Algorithm for the treatment of hyperthyroidism during pregnancy.</p>
    </sec>
    <sec id="sec5">
      <title>5. Conclusion</title>
      <p>Our study highlights a high obstetric morbidity associated with hyperthyroidism during pregnancy, favored by limited resources, irregular follow-up, and poorly controlled hyperthyroidism. Persistent lack of postpartum contraception, mainly due to fear of contraception, exposes patients to unplanned pregnancies and recurrent maternal and fetal complications. The observed correlation between exophthalmos and obstetric complications suggests that clinical severity of hyperthyroidism is associated with poor obstetric outcomes. These findings emphasize the need to improve access to antithyroid treatments, particularly propylthiouracil, and to strengthen regular multidisciplinary follow-up to optimize maternal and fetal outcomes. We propose below a management algorithm.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Alexander, E.K., Pearce, E.N., Brent, G.A., Brown, R.S., Chen, H., Dosiou, C., <italic>et al</italic>. (2017) 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum. <italic>Thyroid</italic>, 27, 315-389. https://doi.org/10.1089/thy.2016.0457 <pub-id pub-id-type="doi">10.1089/thy.2016.0457</pub-id><pub-id pub-id-type="pmid">28056690</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/thy.2016.0457">https://doi.org/10.1089/thy.2016.0457</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Alexander, E.K.</string-name>
              <string-name>Pearce, E.N.</string-name>
              <string-name>Brent, G.A.</string-name>
              <string-name>Brown, R.S.</string-name>
              <string-name>Chen, H.</string-name>
              <string-name>Dosiou, C.</string-name>
            </person-group>
            <year>2017</year>
            <article-title>2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum</article-title>
            <source>Thyroid</source>
            <volume>27</volume>
            <pub-id pub-id-type="doi">10.1089/thy.2016.0457</pub-id>
            <pub-id pub-id-type="pmid">28056690</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Zakiri, B. (2023) Les hyperthyroïdies gravidiques. Thèse Med., Université Cadi Ayyad, N° 0315, 141 p.</mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Zakiri, B.</string-name>
              <string-name>Ayyad, N</string-name>
            </person-group>
            <year>2023</year>
            <article-title>Les hyperthyroïdies gravidiques</article-title>
            <source>Thèse Med.</source>
            <volume>141</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <citation-alternatives>
          <mixed-citation publication-type="web">Borson-Chazot, F. and Caron, P. (2017) Thyroïde et Grossesse. https://www.sfdiabete.org/files/files/JNDES/2017/jndes_2017_borson.pdf</mixed-citation>
          <element-citation publication-type="web">
            <person-group person-group-type="author">
              <string-name>Borson-Chazot, F.</string-name>
              <string-name>Caron, P.</string-name>
            </person-group>
            <year>2017</year>
            <article-title>Thyroïde et Grossesse</article-title>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Gheorghiu, M.L., Bors, R.G., Gheorghisan-Galateanu, A., Pop, A.L., Cretoiu, D. and Varlas, V.N. (2021) Hyperthyroidism in Pregnancy: The Delicate Balance between Too Much or Too Little Antithyroid Drug. <italic>Journal of Clinical Medicine</italic>, 10, Article No. 3742. https://doi.org/10.3390/jcm10163742 <pub-id pub-id-type="doi">10.3390/jcm10163742</pub-id><pub-id pub-id-type="pmid">34442037</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/jcm10163742">https://doi.org/10.3390/jcm10163742</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Gheorghiu, M.L.</string-name>
              <string-name>Bors, R.G.</string-name>
              <string-name>Gheorghisan-Galateanu, A.</string-name>
              <string-name>Pop, A.L.</string-name>
              <string-name>Cretoiu, D.</string-name>
              <string-name>Varlas, V.N.</string-name>
            </person-group>
            <year>2021</year>
            <article-title>Hyperthyroidism in Pregnancy: The Delicate Balance between Too Much or Too Little Antithyroid Drug</article-title>
            <source>Journal of Clinical Medicine</source>
            <volume>10</volume>
            <elocation-id>No</elocation-id>
            <pub-id pub-id-type="doi">10.3390/jcm10163742</pub-id>
            <pub-id pub-id-type="pmid">34442037</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Gadiaga, A. (2003) Etude sur les hyperthyroïdies et la grossesse au CHU de Dantec à Dakar, 2003. Thèse Med., UCAD, N° 80, 117 p.</mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Gadiaga, A.</string-name>
              <string-name>UCAD, N</string-name>
            </person-group>
            <year>2003</year>
            <article-title>Etude sur les hyperthyroïdies et la grossesse au CHU de Dantec à Dakar, 2003</article-title>
            <source>Thèse Med.</source>
            <volume>117</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Aggarawal, N., Suri, V., Singla, R., Chopra, S., Sikka, P., Shah, V.N., <italic>et al</italic>. (2014) Pregnancy Outcome in Hyperthyroidism: A Case Control Study. <italic>Gynecologic and Obstetric Investigation</italic>, 77, 94-99. https://doi.org/10.1159/000357615 <pub-id pub-id-type="doi">10.1159/000357615</pub-id><pub-id pub-id-type="pmid">24481256</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000357615">https://doi.org/10.1159/000357615</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Aggarawal, N.</string-name>
              <string-name>Suri, V.</string-name>
              <string-name>Singla, R.</string-name>
              <string-name>Chopra, S.</string-name>
              <string-name>Sikka, P.</string-name>
              <string-name>Shah, V.N.</string-name>
            </person-group>
            <year>2014</year>
            <article-title>Pregnancy Outcome in Hyperthyroidism: A Case Control Study</article-title>
            <source>Gynecologic and Obstetric Investigation</source>
            <volume>77</volume>
            <pub-id pub-id-type="doi">10.1159/000357615</pub-id>
            <pub-id pub-id-type="pmid">24481256</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Guendouz, F., Boussouf, H. and Hammoune, N. (2017) Etiology of Hyperthyroidism in Pregnancy. <italic>International Journal of Advanced Research</italic>, 5, 916-918. https://doi.org/10.21474/ijar01/6038 <pub-id pub-id-type="doi">10.21474/ijar01/6038</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.21474/ijar01/6038">https://doi.org/10.21474/ijar01/6038</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Guendouz, F.</string-name>
              <string-name>Boussouf, H.</string-name>
              <string-name>Hammoune, N.</string-name>
            </person-group>
            <year>2017</year>
            <article-title>Etiology of Hyperthyroidism in Pregnancy</article-title>
            <source>International Journal of Advanced Research</source>
            <volume>5</volume>
            <pub-id pub-id-type="doi">10.21474/ijar01/6038</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Feki, M., Omar, S., Menif, O., Tanfous, N.B., Slimane, H., Zouari, F., <italic>et al</italic>. (2008) Thyroid Disorders in Pregnancy: Frequency and Association with Selected Diseases and Obstetrical Complications in Tunisian Women. <italic>Clinical Biochemistry</italic>, 41, 927-931. https://doi.org/10.1016/j.clinbiochem.2008.05.002 <pub-id pub-id-type="doi">10.1016/j.clinbiochem.2008.05.002</pub-id><pub-id pub-id-type="pmid">18538668</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.clinbiochem.2008.05.002">https://doi.org/10.1016/j.clinbiochem.2008.05.002</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Feki, M.</string-name>
              <string-name>Omar, S.</string-name>
              <string-name>Menif, O.</string-name>
              <string-name>Tanfous, N.B.</string-name>
              <string-name>Slimane, H.</string-name>
              <string-name>Zouari, F.</string-name>
            </person-group>
            <year>2008</year>
            <article-title>Thyroid Disorders in Pregnancy: Frequency and Association with Selected Diseases and Obstetrical Complications in Tunisian Women</article-title>
            <source>Clinical Biochemistry</source>
            <volume>41</volume>
            <pub-id pub-id-type="doi">10.1016/j.clinbiochem.2008.05.002</pub-id>
            <pub-id pub-id-type="pmid">18538668</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Morax, S. and Badelon, I. (2009) L’exophtalmie Basedowienne. <italic>Journal Franç</italic><italic>ais d</italic>’ <italic>Ophtalmologie</italic>, 32, 589-599. https://doi.org/10.1016/j.jfo.2009.09.001 <pub-id pub-id-type="doi">10.1016/j.jfo.2009.09.001</pub-id><pub-id pub-id-type="pmid">19853965</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jfo.2009.09.001">https://doi.org/10.1016/j.jfo.2009.09.001</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Morax, S.</string-name>
              <string-name>Badelon, I.</string-name>
            </person-group>
            <year>2009</year>
            <article-title>L’exophtalmie Basedowienne</article-title>
            <source>Journal Français d’Ophtalmologie</source>
            <volume>32</volume>
            <pub-id pub-id-type="doi">10.1016/j.jfo.2009.09.001</pub-id>
            <pub-id pub-id-type="pmid">19853965</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Abdous, B. (2016) Hyperthyroïdiennes et Grossesse. <italic>Annales d</italic>’ <italic>Endocrinologie</italic>, 77, 381. https://doi.org/10.1016/j.ando.2016.07.423 <pub-id pub-id-type="doi">10.1016/j.ando.2016.07.423</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ando.2016.07.423">https://doi.org/10.1016/j.ando.2016.07.423</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Abdous, B.</string-name>
            </person-group>
            <year>2016</year>
            <article-title>Hyperthyroïdiennes et Grossesse</article-title>
            <source>Annales d’Endocrinologie</source>
            <volume>77</volume>
            <pub-id pub-id-type="doi">10.1016/j.ando.2016.07.423</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <citation-alternatives>
          <mixed-citation publication-type="web">Caron, M. (2020) Les dysthyroïdies chez la femme enceinte. Application aux apports en iode et en sélénium. https://dumas.ccsd.cnrs.fr/dumas-03213696/document</mixed-citation>
          <element-citation publication-type="web">
            <person-group person-group-type="author">
              <string-name>Caron, M.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>Les dysthyroïdies chez la femme enceinte</article-title>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">King, J.R., Lachica, R., Lee, R.H., Montoro, M. and Mestman, J. (2016) Diagnosis and Management of Hyperthyroidism in Pregnancy: A Review. <italic>Obstetrical &amp; Gynecolog</italic><italic>ical Survey</italic>, 71, 675-685. https://doi.org/10.1097/ogx.0000000000000367 <pub-id pub-id-type="doi">10.1097/ogx.0000000000000367</pub-id><pub-id pub-id-type="pmid">27901552</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/ogx.0000000000000367">https://doi.org/10.1097/ogx.0000000000000367</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>King, J.R.</string-name>
              <string-name>Lachica, R.</string-name>
              <string-name>Lee, R.H.</string-name>
              <string-name>Montoro, M.</string-name>
              <string-name>Mestman, J.</string-name>
            </person-group>
            <year>2016</year>
            <article-title>Diagnosis and Management of Hyperthyroidism in Pregnancy: A Review</article-title>
            <source>Obstetrical &amp; Gynecological Survey</source>
            <volume>71</volume>
            <pub-id pub-id-type="doi">10.1097/ogx.0000000000000367</pub-id>
            <pub-id pub-id-type="pmid">27901552</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Chambon, M. and Cogne, M. (2017) Étude rétrospective de femmes enceintes hospitalisées pour hyperémesis gravidarum révélant une hyperthyroïdie transitoire: Comparaison des formes infracliniques versus thyréotoxicoses. <italic>Annales</italic><italic>d</italic>’ <italic>Endocri</italic><italic>-</italic><italic>nologie</italic>, 78, 234. https://doi.org/10.1016/j.ando.2017.07.266 <pub-id pub-id-type="doi">10.1016/j.ando.2017.07.266</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ando.2017.07.266">https://doi.org/10.1016/j.ando.2017.07.266</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Chambon, M.</string-name>
              <string-name>Cogne, M.</string-name>
            </person-group>
            <year>2017</year>
            <article-title>Étude rétrospective de femmes enceintes hospitalisées pour hyperémesis gravidarum révélant une hyperthyroïdie transitoire: Comparaison des formes infracliniques versus thyréotoxicoses</article-title>
            <source>Annales d’Endocri-nologie</source>
            <volume>78</volume>
            <pub-id pub-id-type="doi">10.1016/j.ando.2017.07.266</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Tamai, H., Kasagi, K., Takaichi, Y., Takamatsu, J., Komaki, G., Matsubayashi, S., <italic>et al</italic>. (1989) Development of Spontaneous Hypothyroidism in Patients with Graves’ Disease Treated with Antithyroidal Drugs: Clinical, Immunological, and Histological Findings in 26 Patients. <italic>The Journal of Clinical Endocrinology &amp; Metabolism</italic>, 69, 49-53. https://doi.org/10.1210/jcem-69-1-49 <pub-id pub-id-type="doi">10.1210/jcem-69-1-49</pub-id><pub-id pub-id-type="pmid">2471711</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1210/jcem-69-1-49">https://doi.org/10.1210/jcem-69-1-49</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Tamai, H.</string-name>
              <string-name>Kasagi, K.</string-name>
              <string-name>Takaichi, Y.</string-name>
              <string-name>Takamatsu, J.</string-name>
              <string-name>Komaki, G.</string-name>
              <string-name>Matsubayashi, S.</string-name>
              <string-name>Clinical, I</string-name>
            </person-group>
            <year>1989</year>
            <article-title>Development of Spontaneous Hypothyroidism in Patients with Graves’ Disease Treated with Antithyroidal Drugs: Clinical, Immunological, and Histological Findings in 26 Patients</article-title>
            <source>The Journal of Clinical Endocrinology &amp; Metabolism</source>
            <volume>69</volume>
            <pub-id pub-id-type="doi">10.1210/jcem-69-1-49</pub-id>
            <pub-id pub-id-type="pmid">2471711</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">American College of Obstetricians and Gynecologists (2015) Practice Bulletin No. 148: Thyroid Disease in Pregnancy. <italic>Obstetrics and</italic><italic>Gynaecology</italic>, 125, 996-1005.</mixed-citation>
          <element-citation publication-type="other">
            <year>2015</year>
            <article-title>Practice Bulletin No</article-title>
            <source>148: Thyroid Disease in Pregnancy. Obstetrics and Gynaecology</source>
            <volume>125</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <citation-alternatives>
          <mixed-citation publication-type="web">Rchachi, M., Houari, H., El Ouahabi, H., Ajdi, F. (2016) Hyperthyroïdie au cours de la grossesse. <italic>Annales d</italic>’ <italic>Endocrinologie</italic>, 77, 389-390. https://www.em-consulte.com/article/1078458/hyperthyroidie-au-cours-de-la-grossesse</mixed-citation>
          <element-citation publication-type="web">
            <person-group person-group-type="author">
              <string-name>Rchachi, M.</string-name>
              <string-name>Ouahabi, H.</string-name>
              <string-name>Ajdi, F.</string-name>
            </person-group>
            <year>2016</year>
            <article-title>Hyperthyroïdie au cours de la grossesse</article-title>
            <source>Annales d’Endocrinologie</source>
            <volume>77</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Hiéronimus, S., Trastour, C., Wagner, K., Hilmi, M. and Brucker-Davis, F. (2017) Hyperémèse gravidique et dysthyroïdie: Quels sont les enseignements d’une cohorte suivie en consultation dédiée «thyroïde et grossesse»? <italic>Annales</italic><italic>d</italic>’ <italic>Endocrinologie</italic>, 78, 260. https://doi.org/10.1016/j.ando.2017.07.127 <pub-id pub-id-type="doi">10.1016/j.ando.2017.07.127</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ando.2017.07.127">https://doi.org/10.1016/j.ando.2017.07.127</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Trastour, C.</string-name>
              <string-name>Wagner, K.</string-name>
              <string-name>Hilmi, M.</string-name>
              <string-name>Brucker-Davis, F.</string-name>
            </person-group>
            <year>2017</year>
            <article-title>Hyperémèse gravidique et dysthyroïdie: Quels sont les enseignements d’une cohorte suivie en consultation dédiée «thyroïde et grossesse»? Annales d’Endocrinologie, 78, 260</article-title>
            <pub-id pub-id-type="doi">10.1016/j.ando.2017.07.127</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Nguyen, C.T. and Mestman, J.H. (2019) Graves’ Hyperthyroidism in Pregnancy. <italic>Current Opinion in Endocrinology</italic>, <italic>Diabetes &amp; Obesity</italic>, 26, 232-240. https://doi.org/10.1097/med.0000000000000492 <pub-id pub-id-type="doi">10.1097/med.0000000000000492</pub-id><pub-id pub-id-type="pmid">31389810</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/med.0000000000000492">https://doi.org/10.1097/med.0000000000000492</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Nguyen, C.T.</string-name>
              <string-name>Mestman, J.H.</string-name>
              <string-name>Endocrinology, D</string-name>
            </person-group>
            <year>2019</year>
            <article-title>Graves’ Hyperthyroidism in Pregnancy</article-title>
            <source>Current Opinion in Endocrinology</source>
            <volume>26</volume>
            <pub-id pub-id-type="doi">10.1097/med.0000000000000492</pub-id>
            <pub-id pub-id-type="pmid">31389810</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Männistö, T., Mendola, P., Grewal, J., Xie, Y., Chen, Z. and Laughon, S.K. (2013) Thyroid Diseases and Adverse Pregnancy Outcomes in a Contemporary US Cohort. <italic>The Journal of Clinical Endocrinology &amp; Metabolism</italic>, 98, 2725-2733. https://doi.org/10.1210/jc.2012-4233 <pub-id pub-id-type="doi">10.1210/jc.2012-4233</pub-id><pub-id pub-id-type="pmid">23744409</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1210/jc.2012-4233">https://doi.org/10.1210/jc.2012-4233</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Mendola, P.</string-name>
              <string-name>Grewal, J.</string-name>
              <string-name>Xie, Y.</string-name>
              <string-name>Chen, Z.</string-name>
              <string-name>Laughon, S.K.</string-name>
            </person-group>
            <year>2013</year>
            <article-title>Thyroid Diseases and Adverse Pregnancy Outcomes in a Contemporary US Cohort</article-title>
            <source>The Journal of Clinical Endocrinology &amp; Metabolism</source>
            <volume>98</volume>
            <pub-id pub-id-type="doi">10.1210/jc.2012-4233</pub-id>
            <pub-id pub-id-type="pmid">23744409</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Dulek, H., Vural, F., Aka, N. and Zengin, S. (2019) The Prevalence of Thyroid Dysfunction and Its Relationship with Perinatal Outcomes in Pregnant Women in the Third Trimester. <italic>Northern Clinics of İstanbul</italic>, 6, 267-272.</mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Dulek, H.</string-name>
              <string-name>Vural, F.</string-name>
              <string-name>Aka, N.</string-name>
              <string-name>Zengin, S.</string-name>
            </person-group>
            <year>2019</year>
            <article-title>The Prevalence of Thyroid Dysfunction and Its Relationship with Perinatal Outcomes in Pregnant Women in the Third Trimester</article-title>
            <source>Northern Clinics of İstanbul</source>
            <volume>6</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Derakhshan, A., Peeters, R.P., Taylor, P.N., <italic>et al</italic>. (2020) Association of Maternal Thyroid Function with Birthweight: A Systematic Review and Individual Participant Data Meta-Analysis. <italic>The Lancet Diabetes &amp; Endocrinology</italic>, 8, 501-510.</mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Derakhshan, A.</string-name>
              <string-name>Peeters, R.P.</string-name>
              <string-name>Taylor, P.N.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>Association of Maternal Thyroid Function with Birthweight: A Systematic Review and Individual Participant Data Meta-Analysis</article-title>
            <source>The Lancet Diabetes &amp; Endocrinology</source>
            <volume>8</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>